3.
血清肿瘤标志物联合检测的诊断价值
The diagnostic significance of combined detection of tumor markers in serum
| Tumor markers combination | Diagnosis | Groups | Sensitivity | Specificity | Accuracy | |
| Case | Control | |||||
| NSE+ProGRP | SCLC | 338 | 244 | 88.90% | 72.82% | 82.16% |
| NSE+CYFRA21-1 | NSCLC, SCC, SCLC | 372 | 212 | 72.90% | 90.30% | 79.22% |
| CEA+NSE | SCLC, NSCLC, adenoCA | 271 | 156 | 71.69% | 93.58% | 79.69% |
| TPS+NSE+CEA | SCLC, NSCLC, adenoCA | 300 | 284 | 90.50% | 84.20% | 80.43% |
| CEA+CYFRA21-1 | SCLC, NSCLC, adenoCA, SCC | 213 | 172 | 80.19% | 93.57% | 86.17% |
| CEA+NSE+CYFRA21-1 | SCLC, NSCLC, adenoCA, SCC | 1 043 | 886 | 87.20% | 86.30% | 86.79% |
| CA125+CA50+CEA | SCLC, NSCLC, adenoCA | 38 | 58 | 97.37% | 78.57% | 89.39% |
| CEA+CA125+CA19-9+CA153 | SCLC, NSCLC, adenoCA | 209 | 245 | 91.39% | 88.45% | 89.81% |
| CA125+CA19-9+CA153 | SCLC, NSCLC, adenoCA | 364 | 354 | 96.17% | 72.96% | 84.73% |
| CEA+CA125+CA19-9 | SCLC, NSCLC, adenoCA | 279 | 215 | 80.64% | 84.45% | 82.30% |
| CYFRA21-1+CA125+CEA | SCLC, NSCLC, adenoCA | 188 | 73 | 85.46% | 59.87% | 78.30% |
| CEA+SCCAg+NSE | SCLC, NSCLC, adenoCA, SCC | 253 | 223 | 85.80 | 94.00% | 89.64% |
| CYFRA21-1+CA50+CEA | SCLC, NSCLC, adenoCA | 131 | 29 | 79.10% | 77.30% | 78.40% |
| CYFRA21-1+CEA+NSE+CA125 | SCLC, NSCLC, adenoCA, SCC | 207 | 68 | 90.33% | 97.50% | 92.10% |
| CYFRA21-1+CA125+NSE | SCLC, NSCLC, adenoCA, SCC | 111 | 80 | 88.55% | 84.10% | 86.69% |
| CA125+CEA+NSE | SCLC, NSCLC, adenoCA | 109 | 90 | 73.10% | 82.28% | 77.25% |
| CEA+CA19-9+SCCAg | SCLC, NSCLC, adenoCA, SCC | 78 | 45 | 70.50% | 86.70% | 74.40% |
| TPS+CYFRA21-1+NSE | NSCLC, SCC, SCLC | 253 | 223 | 88.50% | 90.00% | 89.20% |
| CA153+ Ferrtin +CEA | SCLC, NSCLC, adenoCA | 99 | 25 | 91.90% | 44.00% | 82.19% |
| NSE+CEA+CYFRA21-1+CA19-9 | SCLC, NSCLC, adenoCA | 95 | 48 | 88.42% | 22.92% | 66.43% |
| TSGF+SCCAg+CYFRA21-1 | NSCLC, SCC | 64 | 155 | 95.30% | 74.20% | 80.37% |